TMR

– FDA decision anticipated within four weeks –

TORONTO, June 13, 2025 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the “Trust”) today announced KalVista Pharmaceuticals (“KalVista”) has disclosed that it has received notice from the U.S. Food and Drug Administration (“FDA”) that the FDA will not meet the June 17, 2025 PDUFA goal date for the New Drug Application (NDA) for sebetralstat, due to a heavy workload and agency resourcing issues. KalVista commented that the FDA has not requested additional data or studies and has communicated to KalVista that it anticipates delivering a decision within approximately four weeks.

KalVista issued its own press release with the announcement earlier today (link).

About DRI Healthcare Trust

The Trust is managed by DRI Capital Inc., a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the Trust has deployed more than $1.0 billion, acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. The Trust’s units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol “DHT.UN” and in U.S. dollars under the symbol “DHT.U”. To learn more, visit drihealthcare.com or follow us on LinkedIn.

SOURCE DRI Healthcare Trust

The post DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals’ Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints appeared first on The Malaysian Reserve.

LOS ANGELES, June 13, 2025 /PRNewswire/ — At a hearing today before the California Department of Insurance, State Farm opposed Pacific Palisades homeowner Merritt David Farren’s petition to participate in the ongoing rate review proceedings, citing the Department’s newly announced market conduct examination of the company’s claims handling practices following the January wildfires in Los Angeles. State Farm argued that allegations concerning its failure to properly pay wildfire claims were not relevant to its request for yet another rate hike—despite having already secured a 20% increase in 2024 and a 17% emergency interim increase earlier this year, which is now proposed to be folded into a larger 30% permanent increase.

“State Farm wants to shut the public out because it argues a market conduct exam would take too long,” said Ben Powell, a consumer protection attorney at Consumer Watchdog. “But just weeks ago, State Farm pushed the Department to approve an emergency rate hike with unprecedented speed—even though it hadn’t submitted all the required information. When it comes to raising rates, State Farm demands urgency. But when it comes to protecting consumers, it wants regulators to slam on the brakes.”

Consumer Watchdog emphasized that Proposition 103 guarantees any member of the public the right to intervene in insurance proceedings—a safeguard designed to hold insurers accountable.

“If the Department is willing to act quickly for insurers, it must act just as quickly to protect policyholders,” Powell added. “No one should be excluded from this process—especially not consumers left without fair claim payments after the fires.”

Today’s hearing concluded with the Administrative Law Judge taking the matter under submission. A decision on Mr. Farren’s intervention petition is expected soon.

View original content to download multimedia:https://www.prnewswire.com/news-releases/state-farm-cites-newly-announced-cdi-market-conduct-exam-to-oppose-consumer-participation-in-rate-hearing-says-consumer-watchdog-302481579.html

SOURCE Consumer Watchdog

The post State Farm Cites Newly Announced CDI Market Conduct Exam to Oppose Consumer Participation in Rate Hearing, Says Consumer Watchdog appeared first on The Malaysian Reserve.

It’s Giving Science, Nostalgia, and Serious Chill — No Sunscreen Required!

SAN JOSE, Calif., June 13, 2025 /PRNewswire/ — Skip the sunscreen and crank up the curiosity because summer at The Tech Interactive is bringing serious 90s-inspired vibes. From June 20 to August 3, Silicon Valley’s premier science and technology center will offer extended hours, hands-on experiences, and a full lineup of creative programming for visitors of all ages.

From massive domino builds to throwback dance nights and Hollywood films on the largest IMAX® dome screen on the West Coast, The Tech Interactive is the Bay Area’s go-to destination for cool fun and hands-on learning. The museum will be open until 5 p.m., Tuesday through Sunday, all summer long.

In addition to exploring 130,000 square feet of interactive exhibits, including the new AI-powered Dream Garden, guests can participate in summer workshops and pop-up activities. From building solar ovens for roasting s’mores to experimenting with molecular gastronomy, there’s always something to inspire the innovator in everyone.

“If Summer at The Tech were a mixtape, it’d be packed with science hits, hands-on jams, and blockbuster IMAX tracks,” said Natalie Taylor, VP of Engagement & Experiences at The Tech Interactive. “From building epic domino chains to chilling out after hours at Tech at Nite, it’s going to be all that and a bag of chips.”

Summer Highlights Include:

Totally IMAXed Out
Beat the heat with blockbusters in the IMAX Dome, including F1 (June 26–July 5), Superman (July 10–20), and The Grateful Dead Movie (Aug. 16–17). Daily edutainment documentaries are free with general admission, including T. Rex, Blue Whales, Wild Rescue, Shark Kingdom, and Fungi.

Wild Rescue in IMAX: Opens June 27
Follow the real-life rescue and rehab journeys of wild animals in this powerful, family-friendly film based on work by the Santa Barbara Wildlife Care Network.

Tech Topple: July 13–19
Watch a team of expert domino and machine builders, led by YouTube’s Flash Domino, construct a 50,000-domino masterpiece. Don’t miss The Big Topple on July 19 at 1 p.m.

Shark Week: July 20–26
Celebrate sharks with themed activities, science pop-ups, and the premiere of Shark Kingdom in IMAX. Bonus: Jaws returns to the dome for a 50th anniversary screening, Aug. 30–Sept. 1.

Sock Skating Rink: July 22–Aug. 3
Glide across a colorful, music-filled rink –no skates required! Just bring your favorite socks.

Tech at Nite: Rewind Edition: July 24 (21+)
Relive your middle school field trip, this time with DJs, drinks, and hands-on experiments! Tickets start at $35.

About The Tech Interactive:
The Tech Interactive is a family-friendly science and technology center in the heart of downtown San Jose. With 130,000 square feet of interactive exhibits, hands-on activities, experimental labs, we empower people to innovate with creativity, curiosity, and compassion. We’re committed to expanding access to STEAM education for all, guided by our mission to inspire the innovator in everyone.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-tech-interactive-announces-totally-rad-summer-lineup-302481576.html

SOURCE The Tech Interactive

The post THE TECH INTERACTIVE ANNOUNCES TOTALLY RAD SUMMER LINEUP appeared first on The Malaysian Reserve.

Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status

COLUMBIA, Md., June 13, 2025 /PRNewswire/ — The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, today submitted written testimony to the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies through its chief executive officer, Jason Menzo, who served as an expert outside witness. In the testimony, Menzo urged the Subcommittee to deliver robust and sustained funding for the National Eye Institute (NEI) in Fiscal Year 2026 and to preserve NEI’s status as an independent institute within the National Institutes of Health (NIH).

“NEI is the only federal institute dedicated exclusively to vision research,” said Jason Menzo, CEO of the Foundation Fighting Blindness. “Its work is restoring sight, advancing precision medicine, and delivering hope to millions of Americans living with retinal diseases. Continued investment is critical to maintaining momentum and achieving breakthroughs for conditions that currently have no cure.”

The Foundation’s testimony highlights how NEI-supported research has led to transformative discoveries, including the first FDA-approved gene therapy for an inherited disease, and emphasizes NEI’s strategic role in public-private collaborations that accelerate treatment development. The Foundation Fighting Blindness and NEI have long shared a close, collaborative partnership to advance high-impact scientific discovery and bring new treatments to patients faster. Vision loss from diseases such as retinitis pigmentosa, macular degeneration, and Stargardt disease currently affects tens of millions and costs the U.S. economy an estimated $134.2 billion annually.

The Foundation emphasized that inconsistent funding stalls clinical trials, closes labs, and risks losing top scientific talent—consequences that are difficult and costly to reverse. The testimony also noted that for every dollar invested in NIH-funded research, $2.56 in new economic activity is generated, making this one of the highest-return investments Congress can make.

“We’re not just talking about restoring sight—we’re talking about protecting America’s leadership in biomedical innovation and supporting economic growth in communities nationwide,” added Menzo.

The Foundation Fighting Blindness urges Congress to:

• Provide strong, sustained funding for NEI in the FY2026 Labor-HHS Appropriations bill; and
• Preserve NEI’s status as an independent institute within NIH to ensure focused, strategic investment in vision science.

The full testimony is available at FightingBlindness.org.

About the Foundation Fighting Blindness
Established in 1971, the Foundation Fighting Blindness is the world’s leading private source of funding for research on retinal degenerative diseases. The Foundation has raised over $954 million toward its mission to prevent, treat, and cure blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and more. Visit FightingBlindness.org for more information.

Media Contacts:
Chris Adams
Vice President, Marketing & Communications
[email protected]
(410) 423-0585

View original content to download multimedia:https://www.prnewswire.com/news-releases/foundation-ceo-provides-expert-testimony-to-us-senate-as-outside-witness-on-vision-research-funding-302481562.html

SOURCE Foundation Fighting Blindness

The post Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding appeared first on The Malaysian Reserve.

VANCOUVER, BC, June 13, 2025 /CNW/ – WALL FINANCIAL CORPORATION (TSX: WFC) (the “Company”) announces the voting results from its annual general meeting of shareholders held on June 12, 2025 in Vancouver, British Columbia (the “AGM”).

A total of 27 shareholders were represented at the meeting, being 80.4% of the Company’s issued and outstanding common shares. Shareholders voted in favour of all matters brought before the AGM including setting the numbers at seven, and the appointment of auditors for the ensuing year.

Detailed results of the proxy votes for the election of directors are provided below:

About Wall Financial Corporation

Wall Financial Corporation is a B.C. based real estate company active in the development and management of residential and commercial rental units, development and construction of residential housing for resale, and the development and management of hotel properties.

SOURCE Wall Financial Corporation

The post WALL FINANCIAL CORPORATION ANNOUNCES VOTING RESULTS FROM ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD ON JUNE 12, 2025 appeared first on The Malaysian Reserve.

OTTAWA, ON, June 13, 2025 /CNW/ –

Summary

• Product: Oracare Baby Brush toothbrush
• Issue: Health products – Product safety
• What to do: Immediately stop using the Oracare Baby Brush toothbrush intended for children. Return the product to the store where you purchased it for a refund.

Affected products

• Oracare Baby Brush toothbrush

Issue
Health Canada is advising consumers about a recall of the Oracare Baby Brush toothbrush sold at Dollarama stores across Canada. The toothbrush may pose a choking hazard due to a manufacturing defect that can cause it to break into two pieces.  

Dollarama has received 1 consumer complaint concerning this manufacturing defect; however, there have been no choking incidents reported to the company or Health Canada to date.

Dollarama has advised Health Canada that it will no longer import or sell the Oracare Baby Brush toothbrush.

The company is advising consumers, especially parents and caregivers of children, to stop using this product and return it to Dollarama for a refund.

Health Canada will continue to monitor the situation and will take appropriate and timely action should new information become available.

What you should do

• Stop using the Oracare Baby Brush toothbrush immediately.
• Seek immediate medical attention from a health care professional if injury has occurred from using Oracare Baby Brush toothbrush.
• Report any health product-related side effects or complaints to Health Canada.

Également disponible en français

SOURCE Health Canada (HC)

The post Public Advisory – Oracare Baby Brush toothbrush recalled from Dollarama due to a potential choking hazard appeared first on The Malaysian Reserve.